Thermo and Michael J. Fox Foundation Collaborate to Advance Proteomics-Enabled Parkinson’s Therapy

What happened

Thermo Fisher completed an Olink Explore HT proteomic analysis of approximately 5,500 research samples from the Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, available to the global research community.

Why it matters

The project creates a large-scale proteomics resource to help researchers study Parkinson’s disease at the protein level and investigate biological signals associated with disease progression, patient heterogeneity, and potential biomarker development. This supports the shift toward biology-driven precision medicine.